Please login to the form below
Healthcare terms - R
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare terms - R
- Random samplings
- Randomisation
- Randomised trial
- Range
- Rate card
- Reach
- Readership
- Recall test
- Recession
- Reciprocal links
- Recognition tests
- Recruiting
- Recruitment status
- Reference group
- Reference pricing
- Registered trademark
- Regression analysis
- Reimbursement
- Reinforcement advertising
- Relationship marketing
- Relative advantage
- Relative market share
- Repositioning
- Reprint
- Research and development (R&D)
- Research proposal
- Respondent
- Respondent fatigue
- Response bias
- Response rate
- Responsiveness
- Return on equity (ROE)
- Return on investment (ROI)/Return on capital employed (ROCE)
- Return on sales enablement (ROSE)
- Risk analysis
- Risk-benefit analysis
- Routine response behaviour
- Royal Pharmaceutical Society of Great Britain (RPSGB)
- RSS
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- How the Royal Society’s EiR programme can help to drive UK innovation
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- Lack of evidence for AstraZeneca’s COVID-19 vaccine says UK Department of Health
- NHS England outlines measures to boost capacity ahead of substantial winter pressures
- New research shows drug candidate may effectively treat antibiotic-resistant bacteria
- Sanofi and NIHR enrol first patient in immunisation study for RSV in infants
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- FDA approves Incyte’s Pemazyre as first targeted drug for bile duct cancer
- WHO, UNICEF and UNAIDS launch global alliance to end AIDS in children by 2030
- Creating content to trigger behaviour change
- Strategic commitment
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
